TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38395824
Drug: SRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP with systemic antibiotic administration (spiramycin and metronidazole)
Study: 38395969
Drug: nDC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nDC treatment
Study: 38396126
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 90 mg vitamin C, 30 mg α-tocopherol (vitamin E), 18 mg vitamin B
Study: 38396134
Drug: Carboplatin administration
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administration before sonication
Study: 38398474
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation and oral antibiotics
Study: 38398474
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mechanical bowel preparation and oral antibiotics)
Study: 38398703
Drug: Chronic, latent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic, latent toxoplasmosis treatment
Study: 38400193
Drug: Ad26.ZEBOV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV and MVA-BN-Filo vaccines
Study: 38400780
Drug: ONC201 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 administered D1D2 (twice-weekly)
Study: 38400780
Drug: ONC201 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 administered once-weekly (D1)
Study: 38400919
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum (300 mg)
Study: 38401036
Drug: L-Glutamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (0.1 g/kg twice daily, 0.3 g/kg twice daily, 0.6 g/kg once daily)
Study: 38401036
Drug: L-Glutamine (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (multiple doses over 3 weeks)
Study: 38401036
Drug: L-Glutamine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (oral therapy)
Study: 38401647
Drug: NOAC monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC monotherapy
Study: 38401647
Drug: NOAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC plus clopidogrel combination therapy
Study: 38401649
Drug: Early UFH
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early UFH administration (iv. bolus of 100 units/kg UFH)
Study: 38401649
Drug: Late UFH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late UFH administration (iv. bolus of 100 units/kg UFH)
Study: 38401789
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy intervention
Study: 38402303
Drug: FluMos-v1 (mosaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluMos-v1 (mosaic influenza nanoparticle vaccine)
Study: 38402361
Drug: Extensive ICU
Normalized name: SET,INFUSION,EXTENSION ICU#B33024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive ICU treatment (invasive ventilation for > 24 hours, continuous renal replacement therapy, or both)
Study: 38402708
Drug: Intermittent low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent low glycemic index therapy (LGIT)
Study: 38402708
Drug: Daily low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low glycemic index therapy (LGIT)
Study: 38402886
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg per day)
Study: 38403186
Drug: Bilateral transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) for 15 minutes, twice daily (bid).
Study: 38403793
Drug: Cotadutide (200-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide (200-μg dose)
Study: 38403865
Drug: AZD7442 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (600 mg intramuscular, 300 mg tixagevimab/300 mg cilgavimab)
Study: 38403887
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention including initiation of antiretroviral therapy (ART) during admission, strengths-based case management, and naltrexone
Study: 38404532
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention on oral health
Study: 38405151
Drug: Fludrocortisone (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (lower doses)
Study: 38405151
Drug: Stress dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress dosing
Study: 38406813
Drug: THP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: THP regimen (docetaxel 75 mg/m2, trastuzumab biosimilar TQB211 8 mg/kg first cycle, 6 mg/kg maintenance, pertuzumab biosimilar TQB2440 or pertuzumab 840 mg first cycle, 420 mg maintenance)
Study: 38407317
Drug: Tuvusertib (M1774)
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuvusertib (M1774) 180 mg QD (once daily), 2 weeks on/1 week off treatment
Study: 38407372
Drug: Non-oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-oral route of medication administration
Study: 38407372
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of solid medications (SMs)
Study: 38407372
Drug: Modified medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified medication administration before specialist consultation
Study: 38407372
Drug: Avoidance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoidance of whole SMs administration
Study: 38407508
Drug: Parsaclisib (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib (5, 10, 15, 20, 30, and 45 mg once daily)
Study: 38407601
Drug: Zosuquidar (Zos)
Normalized name: Dynashield ZO
DrugBank: Zosuquidar (DB06191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zosuquidar (Zos) as a 72-h continuous intravenous infusion with chemotherapy (daunorubicin and cytarabine)
Study: 38407601
Drug: Zosuquidar (Zos)
Normalized name: Dynashield ZO
DrugBank: Zosuquidar (DB06191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zosuquidar (Zos) as a 72-h continuous intravenous infusion
Study: 38407859
Drug: Viaskin milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin milk 300 μg
Study: 38407859
Drug: Viaskin milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin milk 300 μg (2 to 11 years age group)
Study: 38407859
Drug: Viaskin milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin milk (all doses)
Study: 38407859
Drug: Viaskin milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viaskin milk 500 μg
Study: 38407974
Drug: DNAase (0.1%)
Normalized name: Recombinant deoxyribonuclease (DNAse)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNAase (0.1%) eye drops four times daily for 8 weeks
Study: 38408060
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (4.5mg)
Study: 38408215
Drug: PrEP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (oral pre-exposure prophylaxis)
Study: 38408443
Drug: Topical Palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Palmitoylethanolamide (Levagen+) applied twice daily for 4 weeks
Study: 38408443
Drug: Standard moisturiser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard moisturiser (comparator) applied twice daily for 4 weeks
Study: 38408457
Drug: Dengue monoclonal
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue monoclonal antibody (1 mg/kg, 3 mg/kg, 7 mg/kg, 12 mg/kg)
Study: 38408457
Drug: Dengue monoclonal
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue monoclonal antibody (1 mg/kg)
Study: 38408457
Drug: Dengue monoclonal
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue monoclonal antibody (3 mg/kg)
Study: 38408457
Drug: Dengue monoclonal
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue monoclonal antibody (7 mg/kg)
Study: 38408457
Drug: Dengue monoclonal
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue monoclonal antibody (12 mg/kg)
Study: 38408457
Drug: Dengue monoclonal
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue monoclonal antibody
Study: 38408729
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of a beverage sweetened with 25% of the ADI of stevia for 4 weeks
Study: 38408729
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of a beverage sweetened with 30 g of sucrose for 4 weeks
Study: 38408999
Drug: Zilovertamab in
Normalized name: Zilovertamab
DrugBank: Zilovertamab (DB18403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilovertamab in combination with paclitaxel
Study: 38409060
Drug: Somatosensory discrimination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatosensory discrimination therapy
Study: 38409060
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb motor therapy
Study: 38409089
Drug: Combination nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination nicotine replacement therapy (NRT) gum + NRT patch
Study: 38409129
Drug: Body Awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Awareness Therapy (BAT) + Pulmonary Rehabilitation (PR)
Study: 38409332
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mesenchymal stromal cell (MSC) infusion
Study: 38410109
Drug: CC-3 bispecific
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-3 bispecific CD276xCD3 antibody, starting dose of 50 µg, with potential increases up to 800 µg depending on safety review.
Study: 38410109
Drug: CC-3 bispecific
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-3 bispecific CD276xCD3 antibody at maximum tolerated dose (MTD) after determination, additional 14 patients.
Study: 38410116
Drug: ELENAGEN (plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELENAGEN (plasmid encoding p62/SQSTM1) in combination with gemcitabine (GEM) 1000 mg/m²
Study: 38410116
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1000 mg/m²
Study: 38410567
Drug: S-HITHOC (cytoreductive
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-HITHOC (cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy)
Study: 38410608
Drug: Consolidative hypofractionated
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidative hypofractionated radiation therapy (hfRT) using stereotactic body radiotherapy (SBRT) starting from 6.5 Gy ×2 fractions and escalating to 10 Gy ×2 fractions, delivered 1 to 2 months after dCRT and concurrently with durvalumab.
Study: 38410608
Drug: Adjuvant anti-PD-L1
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant anti-PD-L1 therapy using durvalumab, delivered concurrently with hfRT.
Study: 38410920
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with durvalumab and tremelimumab
Study: 38410920
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with immunotherapy (durvalumab and tremelimumab)
Study: 38410952
Drug: Acute myocardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute myocardial injury defined as at least 1 high-sensitivity cardiac troponin T value above the upper reference limit (14 ng/L) with a rise/fall of >20%.
Study: 38410945
Drug: Invasive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive management with angiography, revascularization, and guideline-directed medical therapy
Study: 38410945
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative management with guideline-directed medical therapy alone
Study: 38411017
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid during preconception and pregnancy
Study: 38411949
Drug: Mindfulness-Based Compassionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Compassionate Living (MBCL) training, twice a week for 4 weeks
Study: 38411973
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir 1 gm daily for 1 year
Study: 38413147
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose VKA targeting an international normalised ratio of 2.0-3.0
Study: 38413147
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulation
Study: 38413246
Drug: Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination therapy
Study: 38413410
Drug: Asunercept (APG101)
Normalized name: Asunercept
DrugBank: Asunercept (DB15160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunercept (APG101) treatment
Study: 38413540
Drug: Intranasal DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DHE powder (STS101) 5.2 mg
Study: 38413540
Drug: Intranasal DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DHE powder (STS101) 7.0 mg
Study: 38413540
Drug: Intranasal DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DHE powder (STS101) 8.6 mg
Study: 38413540
Drug: Intramuscular DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular DHE mesylate 1.0 mg
Study: 38413540
Drug: Liquid nasal
Normalized name: Zicam Intense Sinus Relief Liquid Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nasal spray DHE 2.0 mg
Study: 38413849
Drug: Chronic beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic beta-blocker therapy
Study: 38413849
Drug: Non-beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-beta-blocker therapy
Study: 38414003
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CrM) supplementation at 20 g/day
Study: 38414510
Drug: Tislelizumab immunotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab immunotherapy
Study: 38414658
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) administration prior to photodynamic therapy (PDT)
Study: 38415895
Drug: Sirolimus drug
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus drug coated balloon (DCB)
Study: 38416223
Drug: THC (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (8 mg THC for a 75-kg person)
Study: 38416223
Drug: THC +
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC + CBD (8 mg THC and 24 mg CBD for a 75-kg person)
Study: 38416809
Drug: Systemic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic metformin (1000 mg/d) with TCA peeling
Study: 38416809
Drug: Systemic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic metformin (500 mg/d) with TCA peeling
Study: 38416865
Drug: Paliperidone Palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone Palmitate Monthly
Study: 38417017
Drug: Automated Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Insulin Delivery System with Automatic Meal Bolus
Study: 38417277
Drug: Glesatinib (MGCD265)
Normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glesatinib (MGCD265) 1050 mg BID (FBS capsule) or 750 mg BID (SDD tablet)
Study: 38417440
Drug: Single-dose camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose camrelizumab alone (n = 20)
Study: 38417552
Drug: 30-mL silicone
Normalized name: CATH,SILICONE 18F 30ML RUSCH #173830180
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mL silicone single-balloon catheter
Study: 38417976
Drug: Dolutegravir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir plus rilpivirine (50 mg dolutegravir plus 25 mg rilpivirine once daily)
Study: 38417976
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current antiretroviral therapy regimen)
Study: 38418234
Drug: Camrelizumab in
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab in combination with chemotherapy (CT)
Study: 38418306
Drug: Advanced ICCU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced ICCU therapies
Study: 38418879
Drug: Tiragolumab (anti-TIGIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab (anti-TIGIT antibody) combined with atezolizumab (anti-PD-L1)
Study: 38419024
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise therapy and education (ExE) and 10-module internet-delivered cognitive behavioral therapy (iCBT)
Study: 38419030
Drug: Stereotactically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactically guided intracerebral injection of CTX0E03, a fetal derived neural stem cell line.
Study: 38419032
Drug: Compressive Cryotherapy
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compressive Cryotherapy (CC)
Study: 38419035
Drug: eclitasertib 600
Normalized name: ECLITASERTIB
DrugBank: SAR443122 (DB16492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eclitasertib 600 mg (300 mg twice daily)
Study: 38419787
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg and 25 mg pooled doses)
Study: 38419981
Drug: Extra-oral suction
Normalized name: Panadol Extra Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-oral suction (EOS) & low suction
Study: 38419981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of suction devices (extra-oral with intra-oral suction, or extra-oral suction with low suction, or high & low suction)
Study: 38420356
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) injection with evidence-based treatment rationale
Study: 38420356
Drug: Fixed-time 'Booster'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-time 'Booster' group with one single repetition of the OLP injection at a fixed time point
Study: 38420356
Drug: On-demand 'Booster'
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand 'Booster' group with one single repetition of the OLP injection on-demand
Study: 38420356
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving just one OLP injection
Study: 38420657
Drug: elranatamab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: elranatamab (12 mg on day 1, 32 mg on day 4, 76 mg on day 8, each cycle = 28 days)
Study: 38420809
Drug: Collagen-related cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-related cell adhesion molecules (CAMs) identified through multi-omics data analysis and bioinformatics.
Study: 38421404
Drug: Venetoclax in
Normalized name: Product containing venetoclax in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax in combination with rituximab
Study: 38421404
Drug: Venetoclax in
Normalized name: Product containing venetoclax in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax in combination with obinutuzumab
Study: 38421404
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment for TLS
Study: 38421421
Drug: LNG-IUS-19.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS-19.5 mg